Search

Warren E Glaab

from Doylestown, PA
Age ~56
Get Report
Also known as:
Warren Glabb, Edwin Glaab Warren
Phone and address:
4580 Summerhill Dr, Gardenville, PA 18901
(215) 345-1355
Related to:
Caryl E Glaab, 59Carl GlaabPatricia J GlaabHannah Glaab, 29Nolan C Glaab, 26Debra J Glaab, 53Rebecca L Glaab, 56
Connected to:
Amanda N Glaab, 28Arthur J Glaab, 87Colleen A Glaab, 64Frank E Glaab, 59James K Glaab, 64John R Glaab, 63Brian P Glaaser, 45Adam M Glab, 31Jeff G Glab, 65Kim M Glab, 57

Warren Glaab Phones & Addresses

  • 4580 Summerhill Dr, Doylestown, PA 18901 (215) 345-1355
  • 1323 Valley Dr, Lansdale, PA 19446 (215) 855-4284
  • 110 Melville Loop, Chapel Hill, NC 27514
  • Brookside, NJ
  • Greensboro, NC
  • Buck, PA
  • 110 Melville Loop APT 3, Chapel Hill, NC 27514

Work

Position: Administrative Support Occupations, Including Clerical Occupations

Publications

Us Patents

Forward Mutation Assay Based On 5-Fluorouracil Resistance

View page
US Patent:
7923204, Apr 12, 2011
Filed:
Apr 22, 2004
Appl. No.:
10/554433
Inventors:
Warren E. Glaab - Doylestown PA, US
Thomas R. Skopek - Collegeville PA, US
Katerina Vlasakova - Hatfield PA, US
Judith E. Miller - Collegeville PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C12Q 1/00
C12Q 1/02
C12Q 1/18
US Classification:
435 4, 435 29, 435 32
Abstract:
Disclosed herein is a novel forward mutation assay based on 5-fluorouracil (5-FU) resistance which utilizes a strain of derived from the Ames strain TA100. More specifically, the invention provides a high throughput alternative to the standard Ames mutation assay for the evaluation of the genotoxicity activity of compounds during an early stage of the drug development process. The invention also identifies the upp locus as a mutational target that is capable of detecting a diverse spectrum of mutagenic events and further describes a tester strain, designated FU100 (his+, rfa, ΔuvrB, pkM101, 5-fluorouridine resistant) for use in the assay of the invention.

Isolated Nucleic Acid Molecules Encoding A Bacterial Uracil Transport Protein And A Bacterial Uracil Phosphoribosyl-Transferase Enzyme, Cells Transformed Therewith And Uses Thereof

View page
US Patent:
20050197497, Sep 8, 2005
Filed:
Sep 25, 2002
Appl. No.:
10/490463
Inventors:
Warren Glaab - Doylestown PA, US
Thomas Skopek - Collegeville PA, US
International Classification:
C12Q001/68
C07H021/04
C07K014/195
C12N001/21
US Classification:
536023500, 435006000, 435252300, 435320100, 530350000
Abstract:
Disclosed herein are novel polynucleotides encoding one of a uracil transport protein and a uracil phosphoribosyl transferase, each being derived from The disclosed uracil phosphoribosyl transferase protein is useful in sensitizing human cancer cells to treatment with anti-cancer agents such as 5-Fluorouracil.

In Vivo Hcv Resistance To Anti-Viral Inhibitors

View page
US Patent:
20100143886, Jun 10, 2010
Filed:
Mar 5, 2008
Appl. No.:
12/529785
Inventors:
Steven W. Ludmerer - North Wales PA, US
Donald J. Graham - Green Lane PA, US
David B. Olsen - Lansdale PA, US
Warren E. Glaab - Doylestown PA, US
International Classification:
C12Q 1/70
C07H 21/04
US Classification:
435 5, 536 231
Abstract:
HCV mutations emerged in chimpanzees treated with a N5B polymerase inhibitor (Compound A) or a NS3 protease inhibitor (Compound B). Short term treatment with Compound A was followed by the initial emergence of an HCV with a S282T polymerase mutation following treatment. Short term treatment with Compound B selected for HCV with a R155K or D168T protease mutation.

Microrna Biomarkers Of Tissue Injury

View page
US Patent:
20110111976, May 12, 2011
Filed:
Apr 24, 2009
Appl. No.:
12/989246
Inventors:
Thomas L. Fare - Furlong PA, US
Philip W. Garrett-Engele - Needham MA, US
Warren E. Glaab - Doylestown PA, US
Jason M. Johnson - Needham MA, US
Omar F. Laterza - New York NY, US
Lee Lim - San Francisco CA, US
Steve W. Ludmerer - North Wales PA, US
David B. Olsen - Lansdale PA, US
Joseph F. Sina - Maple Glen PA, US
Frank D. Sistare - Collegeville PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C40B 30/04
C12Q 1/68
G01N 33/53
US Classification:
506 9, 435 6, 436 94
Abstract:
One aspect of the invention generally relates to use of tissue enriched miRNAs as biomarker to estimate tissue damage in a fluid sample. In a second aspect, methods are provided for monitoring a subject who is exposed or might have been exposed to an agent that has a risk of causing tissue injury. In a third aspect, methods are provided for identifying an agent as having a risk of causing tissue injury to a vertebrate subject. In a fourth aspect, kits are provided for practicing the methods of above-listed aspects. The contents of this ABSTRACT are not intended to in anyway limit the scope of the inventions claimed herein.
Control profile
Warren E Glaab from Doylestown, PA, age ~56 Get Report